Roberfroid Dominique, Huybregts Lieven, Lanou Hermann, Henry Marie-Claire, Meda Nicolas, Menten Joris, Kolsteren Patrick
Child Health and Nutrition Unit, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Am J Clin Nutr. 2008 Nov;88(5):1330-40. doi: 10.3945/ajcn.2008.26296.
Intrauterine growth retardation is a major predictor of child health in developing countries.
We tested whether providing pregnant women with the UNICEF/WHO/UNU international multiple micronutrient preparation (UNIMMAP), rather than iron and folic acid alone, improved fetal growth and its correlates.
An intention-to-treat, double-blind, randomized controlled trial including 1426 pregnancies was carried out in rural Burkina Faso. Tablet intake was directly observed.
Pregnancy outcome was known in 96.3% of the participants. After adjustment for gestational age at delivery, both birth weight (52 g; 95% CI: 4, 100; P = 0.035) and birth length (3.6 mm; 95% CI: 0.8, 6.3; P = 0.012) were significantly higher in the UNIMMAP group. UNIMMAP had a differential effect by percentiles of birth weight and length distributions: the risk of large-for-gestational-age infants was higher in the UNIMMAP group (OR: 1.58; 95% CI: 1.04, 2.38; P = 0.03), although the risk of low birth weight remained unchanged. The effect of UNIMMAP on birth size was modified by maternal body mass index at enrollment and could be more important in multiparous women and women taking sulfadoxine-pyrimethamine. Unexpectedly, the risk of perinatal death was marginally significantly increased in the UNIMMAP group (OR: 1.78; 95% CI: 0.95, 3.32; P = 0.07), and this seemed to affect mainly primiparous women (OR: 3.44; 95% CI: 1.1, 10.7; P for interaction = 0.11).
Maternal UNIMMAP modestly but significantly increased fetal growth. The resulting benefit on infant growth and survival needs to be assessed. The possible lack of benefit and potential harm in primiparous women should be further investigated. This trial was registered at clinicaltrials.gov as NCT00642408.
在发展中国家,宫内生长迟缓是儿童健康的主要预测指标。
我们测试了为孕妇提供联合国儿童基金会/世界卫生组织/联合国大学国际多种微量营养素制剂(UNIMMAP)而非仅铁和叶酸,是否能改善胎儿生长及其相关情况。
在布基纳法索农村地区开展了一项意向性分析、双盲、随机对照试验,纳入1426例妊娠。直接观察片剂服用情况。
96.3%的参与者已知妊娠结局。在对分娩时的孕周进行调整后,UNIMMAP组的出生体重(52克;95%置信区间:4,100;P = 0.035)和出生身长(3.6毫米;95%置信区间:0.8,6.3;P = 0.012)均显著更高。UNIMMAP对出生体重和身长分布百分位数有不同影响:UNIMMAP组大于胎龄儿的风险更高(比值比:1.58;95%置信区间:1.04,2.38;P = 0.03),尽管低出生体重风险保持不变。UNIMMAP对出生大小的影响因入组时孕妇体重指数而异,在经产妇和服用周效磺胺 - 乙胺嘧啶的妇女中可能更显著。出乎意料的是,UNIMMAP组围产期死亡风险略有显著增加(比值比:1.78;95%置信区间:0.95,3.32;P = 0.07),这似乎主要影响初产妇(比值比:3.44;95%置信区间:1.1,10.7;交互作用P = 0.11)。
孕妇服用UNIMMAP适度但显著增加了胎儿生长。由此对婴儿生长和生存产生的益处需要评估。初产妇可能缺乏益处和存在潜在危害的情况应进一步调查。该试验在clinicaltrials.gov注册,注册号为NCT00642408。